

Haidong D Dong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5163454/publications.pdf>

Version: 2024-02-01

139
papers

24,302
citations

19657

61
h-index

13379

130
g-index

144
all docs

144
docs citations

144
times ranked

25467
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. <i>Nature Medicine</i> , 2002, 8, 793-800.	30.7	4,217
2	B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. <i>Nature Medicine</i> , 1999, 5, 1365-1369.	30.7	2,200
3	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. <i>Nature</i> , 2018, 560, 382-386.	27.8	1,836
4	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. <i>Nature Medicine</i> , 2003, 9, 562-567.	30.7	1,157
5	B7-H3: A costimulatory molecule for T cell activation and IFN- γ production. <i>Nature Immunology</i> , 2001, 2, 269-274.	14.5	856
6	Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up. <i>Cancer Research</i> , 2006, 66, 3381-3385.	0.9	788
7	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 17174-17179.	7.1	723
8	Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. <i>Cancer Research</i> , 2005, 65, 1089-96.	0.9	687
9	PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 1757-1761.	7.0	481
10	B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. <i>Cancer Research</i> , 2003, 63, 6501-5.	0.9	401
11	PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata. <i>Cancer</i> , 2007, 109, 1499-1505.	4.1	392
12	PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 580-588.	8.2	388
13	B7-H1 Determines Accumulation and Deletion of Intrahepatic CD8+ T Lymphocytes. <i>Immunity</i> , 2004, 20, 327-336.	14.3	352
14	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , 2017, 129, 3419-3427.	1.4	335
15	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. <i>Cancer Immunology Research</i> , 2015, 3, 610-619.	3.4	327
16	Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 1915-1923.	7.0	313
17	Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. <i>Gastroenterology</i> , 2017, 153, 1107-1119.e10.	1.3	309
18	B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 10391-10396.	7.1	280

#	ARTICLE	IF	CITATIONS
19	Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction. <i>Journal of Experimental Medicine</i> , 2003, 197, 1083-1091.	8.5	259
20	B7-H1 pathway and its role in the evasion of tumor immunity. <i>Journal of Molecular Medicine</i> , 2003, 81, 281-287.	3.9	249
21	Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. <i>Blood</i> , 2000, 96, 2808-2813.	1.4	236
22	Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation. <i>Journal of Immunology</i> , 2004, 173, 6098-6108.	0.8	234
23	Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 5150-5157.	7.0	228
24	Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer. <i>Journal of Immunology</i> , 2011, 186, 6905-6913.	0.8	209
25	B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1036-1040.	1.1	208
26	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. <i>Blood</i> , 2009, 114, 2149-2158.	1.4	202
27	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. <i>Blood</i> , 2001, 97, 1809-1816.	1.4	201
28	Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy. <i>Clinical Cancer Research</i> , 2007, 13, 709s-715s.	7.0	191
29	MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN- γ -Induced B7-H1 Expression in Cholangiocytes. <i>Journal of Immunology</i> , 2009, 182, 1325-1333.	0.8	190
30	Tumor-Infiltrating Foxp3 ⁺ CD4 ⁺ CD25 ⁺ T Cells Predict Poor Survival in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 2075-2081.	7.0	188
31	Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. <i>Journal of Clinical Investigation</i> , 2020, 130, 5380-5396.	8.2	185
32	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 1739.	4.8	174
33	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF- κ B Activation and PD-L1 Expression. <i>Molecular Cell</i> , 2019, 73, 22-35.e6.	9.7	174
34	Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. <i>Cancer</i> , 2005, 104, 2084-2091.	4.1	166
35	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. <i>Journal of Clinical Investigation</i> , 2003, 111, 363-370.	8.2	164
36	B7-H3 Enhances Tumor Immunity In Vivo by Costimulating Rapid Clonal Expansion of Antigen-Specific CD8 ⁺ Cytolytic T Cells. <i>Journal of Immunology</i> , 2004, 173, 5445-5450.	0.8	163

#	ARTICLE	IF	CITATIONS
37	B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. <i>Blood</i> , 2003, 101, 2514-2520.	1.4	157
38	The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality. <i>Immunity</i> , 2019, 51, 491-507.e7.	14.3	148
39	PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. <i>Molecular Cell</i> , 2019, 74, 1215-1226.e4.	9.7	144
40	Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications in De novo Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 5708-5717.	7.0	111
41	TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination. <i>Journal of Immunology</i> , 2009, 183, 3634-3641.	0.8	110
42	Soluble B7-H1: Differences in production between dendritic cells and T cells. <i>Immunology Letters</i> , 2012, 142, 78-82.	2.5	110
43	CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. <i>JCI Insight</i> , 2018, 3, .	5.0	106
44	Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 1749-1756.	7.0	99
45	Immune signatures underlying post-acute COVID-19 lung sequelae. <i>Science Immunology</i> , 2021, 6, eabk1741.	11.9	99
46	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. <i>Frontiers in Immunology</i> , 2017, 8, 961.	4.8	93
47	Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 276-287.	1.1	92
48	Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. <i>American Journal of Reproductive Immunology</i> , 2018, 79, e12795.	1.2	89
49	PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2017, 127, 1960-1977.	8.2	88
50	Costimulation, Coinhibition and Cancer. <i>Current Cancer Drug Targets</i> , 2007, 7, 15-30.	1.6	86
51	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF- κ B. <i>Cancer Research</i> , 2016, 76, 239-250.	0.9	84
52	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. <i>Oncologist</i> , 2019, 24, e1148-e1155.	3.7	81
53	ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. <i>Oncolmmunology</i> , 2020, 9, 1744980.	4.6	77
54	B7-H1 Expressed by Activated CD8 T Cells Is Essential for Their Survival. <i>Journal of Immunology</i> , 2011, 187, 5606-5614.	0.8	74

#	ARTICLE	IF	CITATIONS
55	Contraction of T cell richness in lung cancer brain metastases. <i>Scientific Reports</i> , 2018, 8, 2171.	3.3	74
56	Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. <i>Cancer</i> , 2006, 107, 46-53.	4.1	69
57	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. <i>JCI Insight</i> , 2016, 1, .	5.0	68
58	Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine. <i>Journal of Immunology</i> , 2007, 179, 2860-2869.	0.8	65
59	Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. <i>Cellular and Molecular Immunology</i> , 2006, 3, 179-87.	10.5	65
60	<i>Cryptosporidium parvum</i> Induces B7-H1 Expression in Cholangiocytes by Down-Regulating MicroRNA-513. <i>Journal of Infectious Diseases</i> , 2010, 201, 160-169.	4.0	62
61	The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. <i>Neuro-Oncology</i> , 2020, 22, 967-978.	1.2	62
62	Targeting IFN γ to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. <i>Nature Communications</i> , 2018, 9, 4586.	12.8	60
63	Regulation of sister chromatid cohesion by nuclear PD-L1. <i>Cell Research</i> , 2020, 30, 590-601.	12.0	58
64	Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 22.	6.2	54
65	BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. <i>Oncogene</i> , 2019, 38, 6752-6766.	5.9	52
66	Immunotherapeutic Approaches to Hepatocellular Carcinoma Treatment. <i>Liver Cancer</i> , 2012, 1, 226-237.	7.7	50
67	B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma. <i>Urology</i> , 2005, 66, 10-14.	1.0	48
68	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	48
69	Human Bone Marrow: A Reservoir for Enhanced Effector Memory CD8 ⁺ T Cells with Potent Recall Function. <i>Journal of Immunology</i> , 2006, 177, 6730-6737.	0.8	45
70	Endogenous tumor-reactive CD8 ⁺ T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. <i>OncImmunology</i> , 2013, 2, e23972.	4.6	45
71	B7-H1 Expression on Old CD8 ⁺ T Cells Negatively Regulates the Activation of Immune Responses in Aged Animals. <i>Journal of Immunology</i> , 2010, 184, 5466-5474.	0.8	44
72	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. <i>Melanoma Research</i> , 2020, 30, 364-375.	1.2	42

#	ARTICLE	IF	CITATIONS
73	ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. <i>Developmental Cell</i> , 2022, 57, 329-343.e7.	7.0	42
74	Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. <i>JAMA Network Open</i> , 2020, 3, e200202.	5.9	40
75	PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	40
76	B7-H1 limits the entry of effector CD8 ⁺ T cells to the memory pool by upregulating Bim. <i>Oncolmmunology</i> , 2012, 1, 1061-1073.	4.6	38
77	Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3299-3308.	7.0	37
78	Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. <i>Heliyon</i> , 2018, 4, e01039.	3.2	37
79	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. <i>Scientific Reports</i> , 2019, 9, 10677.	3.3	37
80	B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8 ⁺ T cells. <i>Scientific Reports</i> , 2016, 6, 36722.	3.3	36
81	Immunology of B7-H1 and Its Roles in Human Diseases. <i>International Journal of Hematology</i> , 2003, 78, 321-328.	1.6	34
82	Stem Cells for Murine Interstitial Cells of Cajal Suppress Cellular Immunity and Colitis Via Prostaglandin E2 Secretion. <i>Gastroenterology</i> , 2015, 148, 978-990.	1.3	33
83	CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. <i>Oncotarget</i> , 2016, 7, 70223-70231.	1.8	33
84	Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. , 2020, 8, e001113.		32
85	Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. <i>Clinical Cancer Research</i> , 2022, 28, 3021-3031.	7.0	32
86	Radiation and immunotherapy: emerging mechanisms of synergy. <i>Journal of Thoracic Disease</i> , 2020, 12, 7011-7023.	1.4	28
87	Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. <i>Oncolmmunology</i> , 2017, 6, e1356146.	4.6	27
88	B7-H1 Expression in Vestibular Schwannomas. <i>Otology and Neurotology</i> , 2010, 31, 991-997.	1.3	26
89	Type I ³ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF- κ B. <i>Oncotarget</i> , 2017, 8, 42414-42427.	1.8	26
90	NKG7 Is a T-cell Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 162-181.	3.4	26

#	ARTICLE	IF	CITATIONS
91	Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 229-240.	0.8	24
92	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6376-6383.	7.0	21
93	Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. <i>American Journal of Clinical Pathology</i> , 2017, 148, 441-449.	0.7	19
94	ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses. <i>Cancer Immunology Research</i> , 2021, 9, 952-966.	3.4	19
95	B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System. <i>Frontiers in Immunology</i> , 2017, 8, 1532.	4.8	18
96	Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells. <i>European Urology Focus</i> , 2018, 4, 75-79.	3.1	18
97	Concordance of PD-1 and PD-L1 (B7-1) in paired primary and metastatic clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 2020, 9, 1152-1160.	2.8	17
98	Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. <i>Npj Precision Oncology</i> , 2021, 5, 22.	5.4	17
99	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2015, 126, 834-834.	1.4	17
100	PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF- β 2 receptor I versus II. <i>Cell Reports</i> , 2022, 38, 110349.	6.4	15
101	Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. <i>Nature Immunology</i> , 2020, 21, 365-366.	14.5	14
102	Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2021, 149, 378-386.	5.1	14
103	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , 2021, 11, 86.	6.2	14
104	Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion. <i>Cancers</i> , 2021, 13, 4528.	3.7	14
105	Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. <i>Blood</i> , 2000, 96, 2808-2813.	1.4	14
106	B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 859-867.	4.2	13
107	A Gender Factor in Shaping T-Cell Immunity to Melanoma. <i>Frontiers in Oncology</i> , 2015, 5, 8.	2.8	13
108	Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better. <i>Clinical Cancer Research</i> , 2015, 21, 944-946.	7.0	13

#	ARTICLE	IF	CITATIONS
109	Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 561083.	4.8	12
110	Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11534-11534.	1.6	12
111	First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. <i>Oncologist</i> , 2018, 23, 840-843.	3.7	11
112	Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. <i>Future Oncology</i> , 2019, 15, 2645-2656.	2.4	10
113	Synergy of cancer immunotherapy and radiotherapy. <i>Aging</i> , 2015, 7, 144-145.	3.1	9
114	Immunotherapy in Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 34.	2.2	8
115	Immune resilience in response to cancer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2165-2167.	4.2	8
116	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016, 128, 4392-4392.	1.4	8
117	Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer. <i>BMC Urology</i> , 2022, 22, .	1.4	8
118	Bim is an independent prognostic marker in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , 2018, 78, 97-105.	2.0	7
119	BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. <i>Immunotherapy</i> , 2016, 8, 1351-1353.	2.0	6
120	Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. <i>Nuclear Medicine and Biology</i> , 2021, 100-101, 4-11.	0.6	6
121	Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. <i>BMJ Open</i> , 2022, 12, e050112.	1.9	6
122	Understanding Suboptimal Response to Immune Checkpoint Inhibitors. <i>Advanced Biology</i> , 2023, 7, e2101319.	2.5	5
123	Solid pavestones are needed to pave a solid way to success. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1-1.	4.2	4
124	Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout Mice. <i>Journal of Immunology</i> , 2022, 208, 1845-1850.	0.8	4
125	Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade. <i>Advances in Radiation Oncology</i> , 2022, 7, 100931.	1.2	4
126	The Basic Concepts in Cancer Immunology and Immunotherapy. , 2018, , 1-19.		3

#	ARTICLE	IF	CITATIONS
127	Paradox-driven adventures in the development of cancer immunology and immunotherapy. <i>Genes and Diseases</i> , 2019, 6, 224-231.	3.4	3
128	Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 911-912.	4.2	2
129	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 135.e1-135.e8.	1.6	2
130	Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise. <i>Clinical Cancer Research</i> , 0, , OF1-OF3.	7.0	2
131	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. , 0, .		1
132	Carrying the torch & facing new challenges. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2411-2412.	4.2	0
133	Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2021, 5, 129-135.	0.4	0
134	The reverse signals of costimulatory molecule B7-1 negatively regulate memory CD8 T cell function in tumor immunity. <i>FASEB Journal</i> , 2008, 22, 523-523.	0.5	0
135	Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma. , 2009, , 367-403.		0
136	New Strategies to Improve Tumor Cell Vaccine Therapy. , 2009, , 117-131.		0
137	A novel method to identify and monitor endogenous tumor-reactive T cells by high expression of CD11a (LFA-1) and PD-1 (CD279) as immunologic readout for evaluating the efficacy of PD-1 blockade.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3037-3037.	1.6	0
138	A novel method for identifying downstream signals in tumor-reactive T cells following PD-1 engagement and monitoring endogenous tumor immunity and immunotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3049-3049.	1.6	0
139	A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. <i>SOJ Immunology</i> , 2017, 5, 1-5.	0.2	0